文献速递乳腺癌支持与姑息治疗

脑白质微结构作为乳腺癌化疗后认知下降的风险因素

Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
PubMed 文献 · J Clin Oncol · 2021-09-30

该研究探讨化疗前脑白质微结构是否预测乳腺癌患者化疗后认知下降。对接受蒽环类化疗的乳腺癌患者、未接受全身治疗的乳腺癌患者及无癌对照在化疗前及化疗后6个月、2年、3年进行神经心理测试,并用弥散张量成像测量白质微结构。

要点

  • 化疗前低白质各向异性分数预测乳腺癌化疗后6个月和3年的认知下降。
  • 该预测作用仅见于接受化疗的乳腺癌患者,未见于未化疗乳腺癌患者和无癌对照。
  • 白质微结构可能反映白质储备,低储备是化疗后认知下降的风险因素。

核心结论

  • 低各向异性分数可能反映低白质储备,是乳腺癌化疗后认知下降的风险因素。

研究设计与样本

  • 前瞻性队列研究,纳入接受蒽环类化疗的乳腺癌患者(BC+CT组)、未接受全身治疗的乳腺癌患者(BC-CT组)和无癌对照(NC组)。
  • 神经心理测试在化疗前及化疗后6个月(BC+CT组n=49,BC-CT组n=39,NC组n=37)、2年(n=32、23、29)和3年(n=32、19、28)进行。
  • 使用多变量常模比较评估认知特征偏离程度,用弥散张量成像衍生的各向异性分数(FA)测量治疗前白质微结构。

主要发现

  • FA未预测BC-CT组和NC组的认知下降。
  • 基于体素的分析显示涉及对认知功能至关重要的白质纤维束。

临床怎么用

  • 若未来试验验证,识别低白质储备患者可促进靶向早期干预,或影响患者和医生对化疗的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cognitive decline is frequently observed after chemotherapy. As chemotherapy is associated with changes in brain white matter microstructure, we investigated whether white matter microstructure before chemotherapy is a risk factor for cognitive decline after chemotherapy. METHODS: Neuropsychologic tests were administered before and 6 months (n = 49), 2 years (n = 32), and 3 years (n = 32) after chemotherapy in patients with breast cancer receiving anthracycline-based chemotherapy (BC + CT group), at matched intervals to patients with BC who did not receive systemic therapy (BC - CT group: n = 39, 23, and 19, respectively) and to no-cancer controls (NC group: n = 37, 29, and 28, respectively). Using multivariate normative comparison, we evaluated to what extent the cognitive profiles of patients deviated from those of controls. Fractional anisotropy (FA), derived from magnetic resonance diffusion tensor imaging, was used to measure white matter microstructure before treatment. FA was evaluated as a risk factor for cognitive decline, in addition to baseline age, fatigue, cognitive complaints, and premorbid intelligence quotient. We subsequently ran voxel-wise diffusion tensor imaging analyses to investigate white matter microstructure in specific nerve tracts. RESULTS: Low FA independently predicted cognitive decline early (6 months, P = .013) and late (3 years, P < .001) after chemotherapy. FA did not predict cognitive decline in the BC - CT and NC groups. Voxel-wise analysis indicated involvement of white matter tracts essential for cognitive functioning. CONCLUSION: Low FA may reflect low white matter reserve. This may be a risk factor for cognitive decline after chemotherapy for BC. If validated in future trials, identification of patients with low white matter reserve could improve patient care, for example, by facilitating targeted, early interventions or even by influencing choices of patients and doctors for receiving chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. de Ruiter MB, Reneman L, Kieffer JM, et al. Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer. J Clin Oncol. 2021. PMID: 34591652. doi:10.1200/JCO.21.00627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。